Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis

Diabetology & Metabolic Syndrome

Toshihiko Yanase¹  Hitoshi Nakashima³  Tetsuhiko Yasuno³  Kunihisa Kobayashi²  Tadachika Kudo²  Makito Tanabe¹  Ryoko Nagaishi¹  Kunitaka Murase¹  Yoko Tsutsumi¹  Hiroyuki Takahashi¹  Takashi Nomiyama¹  Yuichi Terawaki¹ 

[1] Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan;Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, 1-1-1 Zokumyouin, Chikushino 818-0067, Fukuoka, Japan;Division of Nephrology and Rheumatology, Department of Internal Medicine, Fukuoka University, School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

关键词: Oxidized low-density lipoprotein;    Linagliptin;    DPP-4 inhibitor;    Hemodialysis;    Type 2 diabetes;   

Others  :  1211824
DOI  :  10.1186/s13098-015-0043-2

 received in 2015-03-05, accepted in 2015-05-13,  发布年份 2015

【 摘 要 】

Background

Incretin therapy is feasible in patients with type 2 diabetes mellitus undergoing hemodialysis (HD). However, few studies have examined the safety and efficacy of this therapeutic approach in patients with diabetes and renal impairment. Here, we examined glycemic control and the anti-oxidative-stress effects of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in patients with type 2 diabetes undergoing HD.

Methods

Thirty-five patients with type 2 diabetes undergoing HD (including 13 insulin-treated patients) were switched from ongoing therapy to linagliptin (5 mg, once daily). Levels of fasting blood glucose, C-peptide immunoreactivity (CPR), glycated albumin, B-type natriuretic peptide, oxidized low-density lipoprotein (oxLDL), high-sensitivity C-reactive protein, 8-hydroxy-2′-deoxyguanosine (8OHdG), body mass index, blood pressure, and other biologic characteristics (liver function, renal function, lipid profile) were determined before and 3 months after linagliptin treatment. Patients were classified into insulin-treated and non-insulin groups.

Results

With the exception of levels of total bilirubin, aspartate aminotransferase, and CPR, none of the patients exhibited changes in glucose metabolism after switching to linagliptin treatment. However, oxLDL levels were decreased significantly by linagliptin therapy in the non-insulin-treated group despite the absence of changes in glycemic control.

Conclusion

Linagliptin can decrease serum levels of oxLDL in patients with type 2 diabetes undergoing HD independent of its glucose-lowering effect.

【 授权许可】

   
2015 Terawaki et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Tsutsumi Y, et al.: The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetology and Metab Synd 2013, 28:10. BioMed Central Full Text
• [2]Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al.: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006, 48:752-60.
• [3]Kao MP, Ang DS, Pall A, Struthers AD: Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010, 24:1-8.
• [4]Pratley RE, Gilbert M: Targeting incretins in type 2 diabetes role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008, 5:73-94.
• [5]Scott D: Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy 2013, 6:359-63.
• [6]Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012, 11:3. BioMed Central Full Text
• [7]Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al.: Glucose-independent improvement of vascular dysfunction inexperimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012, 96:140-9.
• [8]Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S: Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate /insulin-like growth factor ll receptor. Cardiovasc Diabetol 2013, 12:125. BioMed Central Full Text
• [9]Takai S, Sakonjo H, Jin D: Significance of vascular dipeptidyl peptodase-4 inhibition on vascular protection in zucker diabetic fatty rats. J Pharmacol Sci 2014, 125:386-93.
• [10]Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta T, et al.: DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressue. Cardiovasc Diabetol 2014, 13:154. BioMed Central Full Text
• [11]Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahshi H, Tanaka T, et al.: DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressue. Cardiovasc Diabetol 2014, 13:157. BioMed Central Full Text
• [12]Inaba M, Okubo S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al.: CKD expert research group: glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effects of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896-903.
• [13]Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al.: Hyperglycemic pseudohypoxia and complications. Diabetes 1993, 42:801-13.
• [14]Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al.: Hyperglycemic psudohypocomplications. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 1993, 42:801-13.
• [15]Ookawara T, Kawamura S, Kitagawa Y, Taniguchi N: Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction. J Biol Chem 1992, 267:18505-10.
• [16]Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 13:787-90.
• [17]Scheen AJ: Cardiovascular effect of gliptins. Nat Rev Cardiol 2013, 10:73-84.
• [18]Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993, 90:6434-8.
• [19]Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Kume A, et al.: Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery. Diabetes Care 2004, 27:843-4.
• [20]Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al.: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-7.
• [21]Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K: Effects of sitagliptin on 24-H glycemic changes in Japanese patients with type 2 Diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011, 13:699-703.
• [22]Nakamura Y, Tsuji M, Hasegawa H, Kimura K, Fujita K, Inoue M, et al.: Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. Hemodial Int 2014, 18:433-42.
• [23]Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, et al.: GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012, 61:1422-34.
• [24]Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, et al.: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-57.
• [25]Doupis J: Linagliptin: from bench to bedside. Drug Des Devel Ther 2014, 8:431-46.
• [26]Gologhtly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012, 51:501-14.
• [27]Ramos-Arellano LE, Munzo-Valle JF, De la Cruz-Mosso U, Salquado-Bernabe AB, Castro-Alarcon N, Parra-Rojas L: Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects. BMC Cardiovasc Disord 2014, 14:54. BioMed Central Full Text
• [28]Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al.: DPP-4 inhibition on top of angiotension receptor blockade offers a new therapeutic approsch for diabetic nephropathy. Kidney Blood Press Res 2012, 36:119-30.
• [29]Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsupykov O, Reichetzeder C, et al.: Effect of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1 clip hypertension. J Hypertens 2013, 31:2290-8.
• [30]Nakamura Y, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, et al.: Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract 2013, 123:46-51.
• [31]Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M, et al.: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011, 58:979-87.
• [32]Chaykovska L, von Websky K, Rahnenfuhrer J, Alter M, Heiden S, Fuchs H, et al.: Effects of DPP-4 Inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011, 6:e27861.
• [33]Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr: Biology of natriuretic peptides. Am J Cardiol 2008, 101:3-8.
• [34]Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, et al.: Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012, 95:e27-8.